Vertex Pharmaceuticals (VRTX) Other Operating Expenses (2009 - 2026)

Vertex Pharmaceuticals' Other Operating Expenses history runs 18 years deep, the most recent figure standing at $393.5 million for Q1 2026.

• In Q1 2026, Other Operating Expenses fell 48.49% year-over-year to $393.5 million; the TTM figure through Mar 2026 stood at $1.8 billion (down 72.4% YoY), while the FY2025 annual figure was $2.2 billion, down 64.84% from the prior year.
• Other Operating Expenses was $393.5 million for Q1 2026 at Vertex Pharmaceuticals, down from $523.4 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $4.8 billion in Q2 2024 to a low of $240.3 million in Q1 2022.
• Historically, Other Operating Expenses has averaged $682.0 million across 5 years, with a median of $410.6 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses soared 1052.09% in 2024, then plunged 91.48% in 2025.
• A 5-year view of Other Operating Expenses shows it stood at $307.7 million in 2022, then increased by 9.03% to $335.5 million in 2023, then soared by 51.92% to $509.7 million in 2024, then increased by 2.69% to $523.4 million in 2025, then slipped by 24.82% to $393.5 million in 2026.
• The last three Other Operating Expenses figures came in at $393.5 million (Q1 2026), $523.4 million (Q4 2025), and $467.4 million (Q3 2025), per Business Quant data.